Genzyme Company Profile
✉ Email this page to a colleague
What is the competitive landscape for GENZYME, and when can generic versions of GENZYME drugs launch?
GENZYME has nine approved drugs.
There are six US patents protecting GENZYME drugs.
There are two hundred and one patent family members on GENZYME drugs in fifty countries and sixty-four supplementary protection certificates in seventeen countries.
Summary for Genzyme
International Patents: | 201 |
US Patents: | 6 |
Tradenames: | 8 |
Ingredients: | 8 |
NDAs: | 9 |
Patent Litigation for Genzyme: | See patent lawsuits for Genzyme |
Drugs and US Patents for Genzyme
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Genzyme Corp | CERDELGA | eliglustat tartrate | CAPSULE;ORAL | 205494-001 | Aug 19, 2014 | AB | RX | Yes | Yes | 7,196,205 | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
Genzyme | CLOLAR | clofarabine | SOLUTION;INTRAVENOUS | 021673-001 | Dec 28, 2004 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Genzyme | LEUPROLIDE ACETATE | leuprolide acetate | INJECTABLE;INJECTION | 075721-001 | Nov 29, 2001 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Genzyme | MOZOBIL | plerixafor | SOLUTION;SUBCUTANEOUS | 022311-001 | Dec 15, 2008 | AP | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Genzyme Corp | CERDELGA | eliglustat tartrate | CAPSULE;ORAL | 205494-001 | Aug 19, 2014 | AB | RX | Yes | Yes | 11,458,119 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Genzyme
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Genzyme Corp | CAPRELSA | vandetanib | TABLET;ORAL | 022405-001 | Apr 6, 2011 | 6,414,148 | ⤷ Try a Trial |
Genzyme Corp | CAPRELSA | vandetanib | TABLET;ORAL | 022405-001 | Apr 6, 2011 | 7,173,038 | ⤷ Try a Trial |
Genzyme | RENAGEL | sevelamer hydrochloride | TABLET;ORAL | 021179-001 | Jul 12, 2000 | 5,667,775 | ⤷ Try a Trial |
Genzyme | RENAGEL | sevelamer hydrochloride | TABLET;ORAL | 021179-001 | Jul 12, 2000 | 5,496,545 | ⤷ Try a Trial |
Genzyme | RENVELA | sevelamer carbonate | FOR SUSPENSION;ORAL | 022318-002 | Feb 18, 2009 | 7,459,151 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for GENZYME drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 400 mg and 800 mg | ➤ Subscribe | 2008-05-22 |
➤ Subscribe | Powder for Oral Suspension | 0.8 g/packet and 2.4 g/packet | ➤ Subscribe | 2009-12-30 |
➤ Subscribe | Injection | 24 mg/1.2 mL vials (20 mg/mL) | ➤ Subscribe | 2012-12-17 |
➤ Subscribe | Tablets | 800 mg | ➤ Subscribe | 2008-12-04 |
➤ Subscribe | Injection | 1 mg/mL, 20 mL vial | ➤ Subscribe | 2012-02-23 |
➤ Subscribe | Tartrate Capsules | 84mg | ➤ Subscribe | 2018-08-20 |
International Patents for Genzyme Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
South Korea | 20070034499 | ⤷ Try a Trial |
Costa Rica | 20120277 | ⤷ Try a Trial |
Norway | 338324 | ⤷ Try a Trial |
Australia | 2016202591 | ⤷ Try a Trial |
Cyprus | 1113919 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Genzyme Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1411918 | 2012/028 | Ireland | ⤷ Try a Trial | PRODUCT NAME: PLERIXAFOR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR METAL COMPLEX THEREOF; REGISTRATION NO/DATE: EU/1/09/537/001 20090731 |
1244647 | PA2012015,C1244647 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: VANDETANIBUM; REGISTRATION NO/DATE: EU/1/11/749/001, 2012 02 17 EU/1/11/749/002 20120217 |
1244647 | 2012/029 | Ireland | ⤷ Try a Trial | PRODUCT NAME: VANDETANIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/11/749/001-002 20120217 |
0619813 | C300425 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: PLERIXAFOR, DESGEWENST IN DE VORM VAN EEN NIET-TOXISCH ZUURADDITIE ZOUT OF METAALCOMPLEX; REGISTRATION NO/DATE: EU/1/09/537/001 20090731 |
2371361 | LUC00139 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: PLERIXAFOR EVENTUELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE OU UN COMPLEXE METALLIFERE QUI EN DERIVE; AUTHORISATION NUMBER AND DATE: EU/1/09/537/001 20090804 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.